eIF
Inhibitory Selectivity
eIF Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S7369 |
4EGI-14EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with KD of 25 μM. 4EGI-1 specifically inhibits the function of mTOR by blocking the activation of 4E-BP1. 4EGI-1 induces apoptosis. |
Hep3B and PC3 cells were treated with 50 μmol/L 4EGI-1 or 5 μmol/L ABT alone or their combination for 48 hours, and then the cell viability was examined by CCK-8 assay. p, phosphorylated; t, total; T, Thr; S, Ser; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
|
|
| S7370 |
4E1RCat4E1RCat is a dual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction, and inhibits the binding of eIF4G to eIF4E with IC50 of 3.2 μM. |
Immunoblot analysis of IRF7 in wild-type FL-pDCs pretreated with 50 µM 4E1Rcat (4E1R) or DMSO 6 h following stimulation with CpG ODN (1 µM) for 15 min.
|
|
| S8275 |
Tomivosertib (eFT-508)Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
||
| S8181 |
SBI-0640756SBI-0640756 is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex. It can also suppress AKT and NF-kB signaling. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S7369 |
4EGI-14EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with KD of 25 μM. 4EGI-1 specifically inhibits the function of mTOR by blocking the activation of 4E-BP1. 4EGI-1 induces apoptosis. |
Hep3B and PC3 cells were treated with 50 μmol/L 4EGI-1 or 5 μmol/L ABT alone or their combination for 48 hours, and then the cell viability was examined by CCK-8 assay. p, phosphorylated; t, total; T, Thr; S, Ser; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
|
|
| S7370 |
4E1RCat4E1RCat is a dual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction, and inhibits the binding of eIF4G to eIF4E with IC50 of 3.2 μM. |
Immunoblot analysis of IRF7 in wild-type FL-pDCs pretreated with 50 µM 4E1Rcat (4E1R) or DMSO 6 h following stimulation with CpG ODN (1 µM) for 15 min.
|
|
| S8275 |
Tomivosertib (eFT-508)Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
||
| S8181 |
SBI-0640756SBI-0640756 is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex. It can also suppress AKT and NF-kB signaling. |
